Key facts
- SciTech Development’s last known valuation is $64.0M (Jul 2022).
- It has raised $29.6M; the latest was Later Stage VC ($5.5M) in Sep 2025.
- Notable investors include Keiretsu Forum, Harlem River Navy, AIM-HI, CitySide Ventures, Nano Investments — 11 tracked in total.
- SciTech Development has filed 6 Form Ds with the SEC since 2016, most recently Oct 2024 ($240K sold to 2 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for SciTech Development
- ·The full record, as it builds
Funding rounds
No funding rounds for SciTech Development are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SciTech Development
Operator of a biopharmaceutical company intended for cancer treatments through safer drug delivery. The company's delivery platform uses nanovesicles, which are microscopic spheres, to encapsulate drugs that trick cancer cells into absorbing the medication, enabling medical professionals to treat their patients with effective and advanced drugs.
- Sector
- Healthcare
- HQ
- Grosse Pointe Farms, MI, United States
- Founded
- 2001
- Employees
- 12
- Website
- scitechsdp.com/
- Ownership
- Privately Held (backing)
SciTech Development doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SciTech Development shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SciTech Development in its N-PORT filings yet. We sweep new filings monthly.